Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit
Sponsor: Grifols Therapeutics LLC
Listed as NCT04480424, this PHASE2 trial focuses on COVID-19 and remains completed. Sponsored by Grifols Therapeutics LLC, it has been updated 12 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Nov 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Dec 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Grifols Therapeutics LLC
For direct contact, visit the study record on ClinicalTrials.gov .